

PharmaMar Group presents results for the first quarter 2020

- **PharmaMar Group recorded a net profit of €70.6 million in the first quarter.**
- **Sales revenues in the first quarter of 2020 increased by 35% to €24.8 million.**
- **Sales of Yondelis® in the first quarter rose 21% to €20.7 million.**
- **Total revenues for the first quarter of 2020 amounted to €99 million, compared with €19.4 million for the first quarter 2019.**

Madrid, April 23rd, 2020. – PharmaMar Group (MSE: PHM) recorded total sales revenues of €24.8 million for the first quarter of 2020. This represents a growth of 35% compared with the first quarter of last year. Of the above total, €20.7 million correspond to net sales of Yondelis®, which includes €2.3 million of raw material sales to partners. Total sales of Yondelis® increased 21% with respect to the first three months of 2019. In the quarter ending March 31st, 2020, diagnostic sales increased by 44% to €1.9 million, reflecting the launch of the COVID-19 diagnostic test in the second half of March.

With reference to income from licenses, a total of €73.9 million was registered as of March 31st. On January 21st, 2020, PharmaMar received the \$200 million (€181 million) upfront payment from Jazz Pharmaceuticals in connection with the licensing agreement signed in December 2019, which came into force in January 2020. In application of the regulations on revenue recognition (IFRS 15), €73.0 million of this payment was recorded in the first quarter of 2020.

PharmaMar Group's total debt at the end of the first quarter of 2020 was reduced to €60.5 million from €82.7 million at the end of 2019. The Group ended the first quarter with a cash and cash equivalents position of €173.6 million.

PharmaMar Group net profit amounted to €70.6 million to March 31st, 2020, compared with €10.4 million deficit at the same time last year.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com